Entest Biomedical, Inc. Files Patent Application for Selective Targeting of Stem Cells to Lung Using Photoceutical Devices

SAN DIEGO--(BUSINESS WIRE)--Entest BioMedical (OTCBB: ENTB) announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.